What scientists are uncovering about the most debilitating form of PMS

Every month, millions of women experience the familiar physical and emotional shifts that often arise as menstruation draws near. But for those with premenstrual dysphoric disorder (PMDD), the experience “goes far beyond the typical discomfort many people experience before a period,” says Eric Noble, a psychiatrist at Mayo Clinic. 

Instead, PMDD can trigger debilitating symptoms such as severe depression, intense anxiety, rage, emotional distress, hopelessness, and even suicidal thoughts.

For decades, PMDD was “thought to be a disorder of abnormal hormone levels alone,” says Pipal Shah, a psychiatrist and behavioral scientist at Stanford Medicine. But a growing body of research tells a more nuanced story—one rooted not in the hormones themselves, but in how the brain responds to them.

(Are your hormones unbalanced—and what does that even mean?)

Indeed, evidence now increasingly suggests that PMDD stems from a heightened sensitivity to the normal hormonal fluctuations that occur during the menstrual cycle—particularly those involving estrogen, progesterone, and progesterone’s neuroactive byproduct, allopregnanolone. 

Additional factors may also contribute, including altered stress-response systems, differences in brain chemicals like GABA and serotonin, genetics, and disruptions in circadian rhythm regulation.

Together, such insights are reshaping how scientists understand—and increasingly, how they treat—this often-misunderstood condition. 

What PMDD is—and why it’s more than PMS

PMDD is a severe form of premenstrual syndrome (PMS) that affects an estimated 3 to 8 percent of women of reproductive age. It is marked by intense emotional and psychological symptoms that often include depression and a sense of being overwhelmed. 

“Many women with PMDD also experience irritability, rage, anxiety, increased sensitivity to rejection and increased interpersonal conflicts,” says Katie Unverferth, a reproductive psychiatrist and medical director of the maternal mental health program at UCLA Health in California. 

Physical symptoms like headaches, joint pain, and sleep disturbances may also occur. But what sets PMDD apart is its severity and impact on daily life as it “interferes with work, home, or social domains,” says David Rubinow, a distinguished professor of psychiatry at the University of North Carolina–Chapel Hill.

It’s a condition that follows a predictable pattern of symptoms emerging during the luteal phase—the time after ovulation and before menstruation—symptoms that usually improve shortly after a period begins.

And diagnosis “is typically confirmed with prospective symptom tracking over at least two menstrual cycles, since retrospective recall alone is often unreliable,” explains Shah.

Hormones, the brain, or genetics? What drives PMDD symptoms

Recent studies consistently show that individuals with PMDD generally have normal levels of estrogen and progesterone—though earlier theories largely assumed the condition was caused by hormonal imbalances because symptoms appeared so closely tied to the menstrual cycle. 

That assumption made sense because estrogen and progesterone are the primary hormones that regulate the menstrual cycle and both help control ovulation, menstruation, and reproductive function, while also influencing brain systems involved in mood, stress response, and emotional regulation.

(Period pain has long been ignored. That’s changing.)

But we now know that “if you measure the blood hormone levels of someone with PMDD, they won’t be any different from levels of someone without PMDD,” says Liisa Hantsoo, director of research at the Johns Hopkins Reproductive Mental Health Center.

Instead, the difference between women who have PMDD and those who do not appears to lie in sensitivity. “Women with PMDD exhibit an abnormal sensitivity to the normal fluctuations of those hormones,” says Unverferth.

A growing body of research explains why, showing that one key player is allopregnanolone, a compound derived from progesterone that interacts with GABA-A receptors—part of the brain’s primary calming system. While this compound typically has a soothing effect, “it can have the opposite impact in people with PMDD,” says Noble. 

Neuroimaging studies have also pinpointed additional differences in people with PMDD, including heightened activity in the amygdala (a region involved in fear and emotional processing) and reduced regulation by the prefrontal cortex, which helps control emotional responses.

“We have also identified some intrinsic cellular differences that could contribute to the risk of PMDD,” says Peter Schmidt, chief of behavioral endocrinology at the National Institute of Mental Health. For instance, some people with PMDD may process hormonal signals differently at the cellular level, including differences in how certain hormone-sensitive genes are expressed and how cells respond to ovarian hormones.

Genetics may also play a role, Schmidt adds, as research suggests that PMDD runs in families. This is likely due to inherited differences in hormone sensitivity—differences that include how certain genes are turned on or off in hormone-sensitive cells and how those cells respond to ovarian hormones.

Researchers are also increasingly studying the role of sleep and circadian rhythms. “Women with PMDD tend to produce less melatonin,” says Noble—a disruption that can worsen sleep quality, destabilize mood, and create a feedback loop in which poor sleep intensifies emotional symptoms.

Do PMDD symptoms fluctuate by season?

And there are overlapping factors to also consider as well. For instance, many PMDD patients report that their symptoms feel worse at certain times of the year—particularly during seasonal transitions like spring. 

This may occur as seasonal shifts can disrupt sleep patterns and circadian rhythms, both of which already play a key role in regulating mood. And for those sensitive to hormonal fluctuations, these environmental changes may intensify symptoms.

Changes in light exposure that changes with the seasons can also alter melatonin production, potentially worsening existing sleep disruptions in people with PMDD and further amplifying emotional symptoms.

(The menstrual cycle can reshape your brain.)

Still, the evidence of seasonal influences remains limited, and large-scale studies have yet to establish a clear causal link. “I would characterize a spring-worsening pattern as a credible clinical observation in some patients that is also supported by underlying biology, but still largely anecdotal at the population level,” says Shah.

What the science means for treatment and relief

Regardless of seasonal effects and timing, as our understanding of PMDD deepens, treatment approaches are beginning to shift.

“Instead of simply treating symptoms, new treatments for PMDD aim to stop the chain reaction that leads to mood changes in the first place,” says Noble.

One such promising approach involves progesterone-receptor modulators—medications designed to block or alter the body’s response to progesterone. Unlike standard hormonal contraceptives, which typically work by suppressing ovulation and stabilizing hormone fluctuations, these drugs more directly target the hormonal signaling pathways believed to trigger PMDD symptoms. 

For instance, a randomized controlled trial found that ulipristal acetate—a medication that blocks progesterone’s effects—significantly reduces core PMDD symptoms such as mood swings and irritability. 

“It can be thought of as stabilizing progesterone signaling, thus preventing the triggering event,” says Rubinow.

Another emerging therapy is sepranolone, an injectable drug designed to counteract the effects of allopregnanolone at the receptor level. Scientific findings suggest it may also reduce overall symptom severity and improve daily functioning by stabilizing neurosteroid signaling.

Researchers are also exploring the role of circadian-based interventions. Because melatonin and sleep disruption are now known to play a role in PMDD, treatments like timed light exposure or low-dose melatonin are being studied as potential add-ons—though Hantsoo says evidence remains preliminary.

And traditional treatments for people with PMDD remain important as well. For example, hormonal contraceptives can help by suppressing ovulation and stabilizing hormone fluctuations, though their effectiveness is known to vary—especially for emotional symptoms.

Selective serotonin reuptake inhibitors (SSRIs) are another option and remain a first-choice treatment for many doctors. Unlike in major depression, SSRIs “can reduce PMDD symptoms within days instead of weeks,” says Hantsoo—likely because they also affect neurosteroid pathways, not just serotonin.

But because of so many new resources becoming increasingly available, “the field of women’s behavioral health is no longer an ‘orphan’ specialty,” says Schmidt.

For those living with PMDD, this growing range of targeted options offers real hope. “This is an especially promising time for research in PMDD,” says Unverferth, “because we are finally seeing hormone-based therapies for women come to fruition after decades of clinical research.”